The neuroinflammation framework — the recognition that chronic systemic and central nervous system inflammation drives substantial portions of psychiatric illness and cognitive decline — is among the most consequential shifts in psychiatric and neurodegenerative thinking over the past two decades. The classical monoamine hypothesis of depression ("depression is low serotonin") explained some clinical observations but failed to explain why antidepressants take weeks to work, why response is partial in many patients, and why a substantial subset of patients fail to respond to monoamine-targeted treatment entirely. The neuroinflammation framework provides a more complete account that integrates immune biology, stress physiology, metabolic disease, and the lifestyle factors that affect them all.
Microglia are the brain's resident immune cells. They surveil the CNS, respond to injury and infection, prune synapses during development, and modulate inflammation in response to a wide variety of signals. In healthy states, microglia maintain homeostasis and contribute to neuronal health. In chronically activated states — driven by systemic inflammation, chronic stress, metabolic disease, sleep disruption, infection, or aging itself — microglia shift toward pro-inflammatory phenotypes that damage neurons, disrupt synaptic function, and contribute to the cognitive and mood symptoms of psychiatric illness. The clinical implication is that interventions that calm microglial activation have therapeutic potential across multiple psychiatric and neurodegenerative conditions.
Pro-inflammatory cytokines — IL-6, TNF-alpha, IL-1β — are the molecular signals that mediate much of inflammation's effect on the brain. They can be measured peripherally (in blood) and correlate with central inflammation, though the correlation is imperfect. Elevated peripheral cytokines are associated with depression, suicidality, fatigue, anhedonia, sleep disturbance, and cognitive impairment in multiple studies. Patients with autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel disease) have substantially elevated psychiatric comorbidity at rates that cannot be explained by the psychosocial burden of chronic illness alone — the inflammation itself is the contributor.
The bidirectional relationship matters clinically. Depression and chronic stress drive inflammation. Inflammation drives depression. The patient with refractory depression and elevated CRP is in a loop where each side reinforces the other; treating one without addressing the other often produces partial response. The intervention strategy that emerges is multi-modal: treat the depression directly while also addressing inflammatory contributors (sleep, exercise, dietary patterns, metabolic optimization, omega-3 supplementation, specific anti-inflammatory medications in selected cases).
The inflammatory framework reorganizes pharmacology. Some antidepressants have well-characterized anti-inflammatory effects beyond their monoamine actions. Lithium reduces microglial activation. Some atypical antipsychotics have anti-inflammatory effects. Ketamine's rapid antidepressant effect may involve anti-inflammatory mechanisms in addition to glutamate receptor antagonism. Looking at psychiatric medications through the inflammation lens often clarifies why specific agents work in specific patients — the patient with inflamed depression may respond to one agent and not another based partly on the inflammation profile, not just classical receptor pharmacology.
The longevity-psychiatry implication is direct. Neuroinflammation is a core driver of cognitive aging in addition to psychiatric illness — and the interventions that reduce inflammation in midlife protect cognitive trajectory across decades. The patient with chronically elevated CRP at 50 has a measurably different cognitive trajectory at 75 than the patient with low inflammation. The clinical task is to identify inflammation, treat its drivers, and recognize that the work is simultaneously psychiatric and cognitive-protective.